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Abstract
Adult T cell leukemia/lymphoma (ATL) can be susceptible, at least transiently, to treatments with azidothymidine (AZT)
plus IFNα and/or arsenic trioxide. However, the real role of AZT in this effect is still unclear. In fact, while reverse
transcriptase (RT) inhibition could explain reduction of clonal expansion and of renewal of HTLV-1 infected cells during
ATL progression, this effect alone seems insufficient to justify the evident and prompt decrease of the pro-viral load in
treated patients. We have previously demonstrated that AZT is endowed with an intrinsic pro-apoptotic potential
towards both peripheral blood mononuclear cells from healthy donors or some tumor cell lines, but this cytotoxic
potential cannot be fully achieved unless IκBα phosphorylation is inhibited. Since the constitutive activation of NF-
kappa B (NF-κB) appears a common biological basis of HTLV-1-infected cells, a pharmacological inhibition of IκBα
phosphorylation seems a potential strategy for treating and preventing HTLV-1 related pathologies. In this study, we
have demonstrated that a combination treatment with the IκBα phosphorylation inhibitor Bay 11-7085 and AZT
induced increased levels of regulated cell death (RCD) by apoptosis compared to the single treatments in HTLV-1
infected cells of different origin. Importantly, levels of RCD were considerably higher in infected cells in comparison
with the uninfected ones. Inhibition of NF-κB activation following the combined treatment was confirmed by analysis
of both gel-shift and functional activity of the NF-κB complex proteins, p65/p52. Moreover, a transcriptional analysis
revealed that the addition of Bay 11-7085 to AZT treatment in HTLV-1-infected cells modified their transcriptional
profile, by inducing the upregulation of some pro-apoptotic genes together with the downregulation of some anti-
apoptotic genes. Our data suggest that addition of adequate concentrations of IκBα phosphorylation inhibitor to
therapeutic regimens including AZT could be a promising strategy in ATL.
Introduction
Human T-lymphotropic virus type 1 (HTLV-1) is the
etiological agent of both hematologic and neurologic
diseases. The most severe hematologic disorder caused by
HTLV-1 is adult T-cell leukemia/lymphoma (ATL), a
malignancy of CD4+ T-cells1. Regarding to neurologic
disorders, HTLV-1 infected individuals could develop
HTLV-1-associated myelopathy/tropical spastic parapar-
esis (HAM/TSP) or other inflammatory based diseases2–4.
HTLV-1 is diffused in endemic area in Central and
Southern America, Central and Southern Africa, Middle
Est, Japan, or in specific local communities, as recently
found for some Aboriginal Australians groups5,6. Never-
theless, due to increasing migration flows, geographical
distribution of the virus has become ever greater and less
discernible. About 5–10 millions of people are estimated
to be infected worldwide. However, only a total of up to
© The Author(s) 2020
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Beatrice Macchi (macchi@med.uniroma2.it)
1Department of Experimental Medicine, University of Rome “Tor Vergata”,
Rome, Italy
2IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy
Full list of author information is available at the end of the article
These authors contributed equally: Claudia Matteucci, Francesca Marino-Merlo
These authors jointly supervised this work: Antonio Mastino, Sandro Grelli
Edited by A. Rufini
Official journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
10% develop HTLV-1 associated diseases after a period of
long latency. In fact, HTLV-1 persistence is characterized
by profound interactions of virus regulatory proteins with
host cell factors driving cell death/proliferation7,8, and by
activation of the immune system9. Efficacious therapeutic
approaches towards all forms of HTLV-1 related diseases
and/or prophylactic or therapeutic vaccines are not cur-
rently available. Monotherapy with reverse transcriptase
(RT) inhibitors, already used towards HIV, did not sub-
stantially change the course of HTLV-1 associated dis-
eases10,11. Therefore, the implementation of health
interventions to control HTLV-1 infection is a great
challenge for the future12. In particular, ATL is resistant
to classical chemotherapy and the only effective therapy at
the moment, although not curative, is a regimen including
combined treatment of azidothymidine (AZT) plus
interferon alpha (IFNα)13,14 and or arsenic trioxide15–18.
Nevertheless, mechanisms underlying the partial efficacy
of this combination, await further clarifications19,20. Our
previous studies have demonstrated that AZT and other
nucleoside compounds act as potent RT inhibitors
towards HTLV-1 RT activity in vitro21–23. Obviously,
however, RT inhibition cannot affect already infected
ATL clones. Interestingly, recent results suggest that a
continuous reinfection of HTLV-1 clones occurs during
leukemogenesis in ATL24,25. Inhibition of horizontal virus
transmission by AZT could be hindered, anyhow, by con-
tinuous growth of ATL cells favored by mechanisms
counteracting regulated cell death (RCD). The latter include
activation of the transcription factor nuclear factor-κB (NF-
κB)26, tightly regulated by the HTLV-1 proteins Tax and
basic leucine zipper (bZIP) factor (HBZ)27–29.
We have observed that, in addition to its RT inhibitory
activity, AZT has the capability to activate conflicting
apoptosis-related signals. However, only when AZT was
combined with pharmacological inhibition of IκBα phos-
phorylation, cells were actually pushed towards apopto-
sis30–32. The aim of the present study was to investigate
whether the pharmacological inhibition of IκBα phos-
phorylation could potentiate a possible pro-apoptotic
effect exerted by AZT towards HTLV-1 infected cells. To
this purpose, we analyzed the susceptibility to apoptotic
RCD of HTLV-1-infected cell lines following a combina-
tion treatment with AZT and Bay 11-7085.
Results
Pro-apoptotic effects of AZT towards normal and
HTLV-1-transformed cells
In order to evaluate the pro-apoptotic potential of AZT
towards normal and HTLV-1-transformed cells, PBMC
from healthy donors and cells from the chronically
HTLV-1-infected MT-2 cell line, were treated with the
drug at concentrations up to 128 µM. Percentages of
hypodiploid nuclei were then evaluated at 72 h. The
timing of these experiments was based on previous
experience indicating that a time of 24 h after treatment
was too early to observe reasonable levels of apoptosis,
both in PBMC and in MT-2 cells. PBMC, as well as MT-2
cells, showed a low response to apoptosis induction when
exposed to AZT in vitro. In PBMC, an evident increase in
percentage of hypodiploid nuclei, in comparison with
control cells, was observed only at the higher concentra-
tion of 128 µM (Fig. 1a). In MT-2 cells, an even more
noticeable increase of apoptosis occurred at 128 µM in
comparison with control cells (Fig. 1b). This effect was
highly specific without any sign of induction of necrotic
cell death. Taking into account that levels of apoptosis
induced by AZT towards PBMC from healthy donor at
Fig. 1 Apoptotic RCD induced by AZT towards PBMC from healthy donors and MT-2 cells. Percentages of hypodiploid nuclei, detected by flow
cytometry, in AZT treated PBMC (a) and MT-2 cells (b). The cells were treated with medium as a vehicle (CTR) or treated with 8, 32, and 128 µM AZT
for 72 h. The results are expressed as mean values ± S.D. obtained from three independent experiments. Asterisks indicate significant (*p < 0.05) and
highly significant (**p < 0.001) differences between treated and control cells.
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the same concentration and time, even if recognizable,
were less evident, the concentration of 128 µM AZT was
considered for a possible combination treatment.
Effects of pharmacological inhibition of IκBα
phosphorylation on apoptotic regulated cell death in
normal and HTLV-1-transformed cells
To possibly potentiate the pro-apoptotic activity of AZT
towards HTLV-1 transformed cells by means of the pre-
ventive inhibition of NF-κB activation, we performed
dose–effect experiments to assess the ability of Bay11-
7085, a pharmacological inhibitor of IκBα phosphoryla-
tion, to induce apoptosis at 24 h. In PBMC, Bay 11-7085
induced an evident, dose-dependent increase of hypodi-
ploid nuclei at all the concentrations tested, except at
1 µM, in comparison with vehicle (Fig. 2a). Regarding to
MT-2 cells (Fig. 2b), Bay 11-7085 even at the lowest
concentrations of 1 and 2.5 µM induced noticeable
hypodiploid nuclei percentages. Levels of apoptosis dra-
matically increased at higher concentrations, reaching a
plateau of about 63% at 10 μM. Given the necessity to
limit the risk of toxicity by Bay 11-7085, the suboptimal
concentration of 1 µM was chosen for the following
combination experiments with AZT.
Susceptibility of HTLV-1-transformed cells to apoptotic
regulated cell death induced by a combination treatment
with AZT and an inhibitor of IκBα phosphorylation
We then wanted to investigate the effect of a combined
treatment consisting of AZT preceded by inhibition of
IκBα phosphorylation towards cells transformed by
HTLV-1. To this purpose, in addition to MT-2 cells, two
others chronically infected cell lines, amply utilized for
studies on HTLV-1, designated as C5/MJ and C91/PL,
were utilized. All the three cell lines were pre-treated with
Bay 11-7085 at 1 µM for 2 h and subsequently treated with
128 µM AZT. The percentage of hypodiploid nuclei was
then assessed after a further incubation of 72 h, i.e. after
3 days in culture, as well as following a retreatment of the
cells with the same protocol for another 72 h, i.e. after a
total of 6 days in culture. An increase of apoptosis levels in
MT-2 cells following the combination treatment, com-
pared to single treatments, was already evident after
3 days (Fig. 3a). After 6 days in culture and two cycles of
combination treatment, levels of apoptosis of MT-2 cells
were much more dramatically enhanced with respect to
those induced by single treatments (Fig. 3a). The C5/MJ
cell line was found to be less susceptible than MT-2 cells
to AZT alone both after 3 days and after 6 days treatment
(Fig. 3b). At 3 days, the preventive addition of Bay 11-
7085 to AZT treatment induced indeed an increased level
of apoptosis with respect to single treatments, but dif-
ferences were not statistically significant, probably due to
high variability among the independent experiments.
Conversely, after 6 days in culture and the two-cycle
combination treatment, apoptosis induced by AZT in C5/
MJ cells was noticeably increased by preventive Bay 11-
7085 addition with respect to AZT alone. Regarding to the
C91/PL cell line, cells showed to be very sensitive to
apoptosis induced by AZT alone, both after 3 and 6 days
in culture. Combined treatment with AZT and Bay 11-
7085, resulted indeed in a higher apoptotic response at 3
as well as at 6 days (Fig. 3c). However, due to elevated
response to AZT alone, differences with respect to AZT
alone were not statistically significant (Fig. 3c). To verify
whether the combined treatment could be toxic for
uninfected normal cells, PBMC from healthy individuals
were subjected to the same protocol utilized for HTLV-1
transformed cells. The results showed that the AZT
treatment either in the absence or in the presence of 1 µM
Bay 11-7085 did not induce evident levels of hypodiploid
Fig. 2 Apoptotic RCD induced by pharmacological inhibition of
IκBα phosphorylation towards PBMC from healthy donors and
MT-2 cells. Percentages of hypodiploid nuclei, detected by flow
cytometry analysis, were assessed in PBMC (a) and MT-2 (b) cells either
treated with medium as a vehicle (CTR) or treated with medium plus
DMSO at the higher concentration utilized for diluting Bay 11-7085
(DMSO), or treated with 1, 2.5, 5, 10, and 20 μM Bay 11-7085, for 24 h.
The results are expressed as mean values ± S.D. obtained from three
independent experiments. Asterisks indicate significant (*p < 0.05) and
highly significant (**p < 0.001) differences between treated and
CTR cells.
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nuclei at 3 days in culture (Fig. 3d). After 6 days in culture,
apoptosis level following the combined treatment,
although increased with respect to the previous timing,
was still relatively low, and no statistically significant
difference with respect to control cells was assessed.
To confirm that increased levels of hypodiploid nuclei
following combination treatment with AZT and Bay 11-
7085 in HTLV-1 infected cells were actually related to the
apoptotic form of RCD, further experiments on MT-2
cells were carried out using the Annexin-V/PI staining, as
detected by flow cytometry, and cleavage of caspase 3 and
PARP-1, as detected by Western blot analysis, as addi-
tional markers of apoptotic cell death. Results, reported in
Supplementary Information 2, clearly confirmed that the
combination treatment with AZT and Bay 11-7085
induced higher levels of cell death in HTLV-1 infected
cells with respect to single treatments and that cells
underwent cell death with the classical feature of apop-
tosis. Therefore, altogether these results showed a con-
sistent, although variable, response of HTLV-1
transformed cells to apoptotic RCD induced by a com-
bination treatment with AZT preceded by an inhibitor of
IκBα phosphorylation, while the same combination
treatment did not substantially change levels of apoptosis
in PBMC from healthy individuals.
Effects of the combination treatment with AZT and an
inhibitor of IκBα phosphorylation towards cells infected
in vitro by HTLV-1, but not yet transformed
To get information on the effects of the combination
treatment with AZT and the inhibitor of IκBα phosphor-
ylation on cells infected by HTLV-1 during the phase that
precede the eventual transforming event, we used IL-2-
dependent cell cultures infected in vitro with HTLV-1 in
our laboratory, at different times a.i.. In particular, BM24, at
12 weeks a.i., and BM7, at 52 weeks a.i., were assayed at 72 h
after treatment. Regarding to BM24, preventive inhibition
of NF-κB activation rendered these cells high susceptible to
apoptosis induced by AZT in comparison with AZT alone
(Fig. 4a). Similarly, also BM7 cells were highly susceptible to
the induction of apoptotic RCD by the combination treat-
ment (Fig. 4b). However, presumably due to high inter-
experimental variability and to high level of apoptosis
induced Bay 11-7085 alone, no statistical difference was
observed between BM7 cells treated with the inhibitor of
IκBα phosphorylation alone and the combination
Fig. 3 Apoptotic RCD induced by a combination treatment with AZT and an inhibitor of IκBα phosphorylation towards HTLV-1 chronically
infected cell lines. Percentages of hypodiploid nuclei, detected by flow cytometry, in MT-2 (a), C5/MJ (b), and C91/PL (c) cells, or PBMC from healthy
donors (d), after treatment with vehicle (CTR), with 128 µM AZT (AZT), with 1 µM Bay 11-7085 (BAY), or pre-treatment with 1 µM Bay 11-7085 for 2 h
and subsequent treatment with 128 µM AZT (AZT+BAY) for 72 h, i.e. after a total of 3 days in culture (day 3) or following a second retreatment with
the same protocol for another 72 h, i.e. after a total of 6 days in culture (day 6). The results are expressed as mean values ± S.D. obtained from three
independent experiments. Asterisks indicate significant (*p < 0.05) and highly significant (**p < 0.001) differences between groups (connection bars).
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treatment. Thus, also in cells infected in vitro by HTLV-1,
but not-yet-transformed, the apoptotic response to the
combination treatment was consistently higher in com-
parison with that obtained by AZT alone.
Effects of the combination treatment with AZT and an
inhibitor of IκBα phosphorylation on NF-κB activation
To investigate whether effects exerted by the combi-
nation treatment were associated to the modulation of the
NF-κB complex, MT-2 cells subjected to various treat-
ments were assayed immediately before starting any
treatment (T0), and at 1 and 24 h after the last treatment.
Firstly, NF-κB activation was detected using EMSA (Fig. 5a).
As assessed by the comparison of the bands of the treated
samples and of the corresponding control samples, the
inhibition of NF-κB complex activation remarkably
occurred early after 1 h following the combination treat-
ment. AZT treatment itself induced a slighter inhibition
of NF-κB activation at the early time, but an increase of
the NF-κB complex at the late time, after 24 h, suggesting
that the cells were in a rebounding phase from the first
AZT treatment. In fact, in this case the addition of Bay 11-
7085 partly counteracted the AZT-driven rebound, so
that a lower difference, with respect to control cells, was
observed at 24 h in comparison with AZT alone treated
cells. On the contrary, the single treatment with Bay 11-
7085 was unable to induce relevant changes in compar-
ison with control at the detection times utilized for these
experiments (Fig. 5a). Notice that differences in the band
feature of CTRL samples at different times of treatment
indicates that basal levels of NF-κB varied depending on
the growth phase in culture and strongly recommended to
compare treated samples limited to corresponding CTRL
sample. We then sought to achieve further details on this
issue by analyzing the DNA-binding activity of the single
p65, p50, and p52 phosphorylated proteins in the cellular
nuclear lysates from MT-2 cells treated as for EMSA. The
results, shown in Fig. 5b, demonstrated that the DNA-
binding activity of phosphorylated p50 was not modulated
with respect to the control in any of the experimental
conditions tested, except for the combination treatment at
24 h. Conversely, the DNA-binding activity of phos-
phorylated p65 and p52 was remarkably modulated in the
different culture conditions. Actually, Bay 11-7085
inhibited p65 binding at 1 h after treatment with respect
to control. Conversely, the same single treatment
increased p65 binding at 24 h in comparison with the
corresponding control, while only slight differences were
observed between AZT and AZT plus Bay 11-7085 trea-
ted and control samples, with cells subjected to the
combination treatment showing the lower levels of p65
binding. Regarding p52, the results showed a noticeable
downregulation of this activity at 1 h following the com-
bination treatment with respect to the control, while no
evident modification after single treatments. At 24 h after
treatment, the DNA-binding activity of p52 was higher in
comparison with corresponding control following single
treatments, but not following the combination treatment.
These assays were performed also in C5/MJ cells, where
we obtained a trend in the effects of single and combi-
nation treatments that was similar to that observed in
MT2 cells, except for the significance of some differences
and for the effect of the combination treatment at 24 h,
where a significant recovery in the binding activity of the
p65 protein was observed (see Supplementary Informa-
tion 3). In summary, these results indicate that the
eventual effect of the combination treatment on the
activation of the NF-κB complex should be considered the
sum of the different balance of both p65 and p52 but not,
or less importantly, p50 activities.
Fig. 4 Apoptotic RCD induced by a combination treatment with AZT and an inhibitor of IκBα phosphorylation towards not-yet-
transformed, in vitro HTLV-1 infected cells. Percentages of hypodiploid nuclei were assessed in IL-2 dependent, in vitro HTLV-1 infected BM24 (a)
and BM7 (b) cell cultures, at 12 and 52 weeks in culture, respectively, from infection, following treatment with vehicle (CTR), with 128 µM AZT (AZT),
with 1 µM Bay 11-7085 (BAY), or pre-treatment with 1 µM Bay 11-7085 for 2 h and subsequent treatment with 128 µM AZT (AZT+BAY) for 72 h. The
results are expressed as mean values ± S.D. obtained from three independent experiments. Asterisks indicate significant (*p < 0.05) and highly
significant (**p < 0.001) differences referred to CTR cells (no connection bar) or between groups (connection bars).
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Effects of the combination treatment with AZT and an
inhibitor of IκBα phosphorylation on the expression of
cellular and viral genes
In order to get further information on mechanisms
involved in the effects of the combination treatment with
AZT plus Bay 11-7085 on RCD in HTLV-1-transformed
cells, the expression of relevant cellular genes was inves-
tigated. As a preliminary experimental approach, a com-
mercial gene array for analysing the expression profile of
genes related to apoptosis and cell cycle was employed on
MT-2 cells treated for 24 h. The results showed that the
combination treatment induced the modulation of both
pro- and anti-apoptotic genes (Supplementary Informa-
tion 4). To confirm results obtained with the SuperArray
analysis, a selected number of pro- and anti-apoptotic
genes (underlined in Supplementary Information 4)
recognized as targets of NF-κB, were chosen for quanti-
tative analysis of gene expression by RQ-PCR in MT-2 or
C5/MJ cells, at 24 h after single or combined treatments.
The relative mRNA level analysis confirmed the mod-
ulation of both pro- and anti-apoptotic genes following
different treatments, in both the cell lines. In MT-2 cells, a
general upregulation of genes associated with cell death
induction pathways in response to the treatments was
observed (Fig. 6a). In particular, levels of mRNA for all
genes designated as pro-apoptotic, except for BAX, were
slightly higher than control samples in response to the
single treatment with AZT. Conversely, the expression of
the same genes was considerably upregulated, in respect
to the control samples, in response to single treatment
Fig. 5 Detection of NF-κB activation in MT-2 cells treated with AZT and an inhibitor of IκBα phosphorylation. MT-2 cells were either treated
with vehicle (CTR) or treated with 1 µM Bay 11-7085 alone (BAY), 128 µM AZT alone (AZT), or with both (AZT+BAY), and then assayed at 1 and 24 h
after the last treatment for NF-κB DNA-binding activity using non-radioactive electro-mobility shift assay (EMSA) (a), or detection of phosphorylated
p65, p50 and p52 binding by an enzyme-linked immunosorbent assay (ELISA) (b). a A representative gel (upper side) and results of densitometry
analysis (lower side) expressed as mean values ± S.D. obtained from three gels generated in independent experiments. T0 sample refers to cells
assayed by immediately before starting any treatment. b The histograms represent the mean values ± S.D. from three independent experiments and
are expressed as the ratio of the values obtained from samples of the experimental groups versus those obtained in samples of the CTR group at
24 h. Asterisks indicate significant (*p < 0.05) and highly significant (**p < 0.001) differences referred to the CTR group at 1 h (no connection bar) or
between groups (connection bars).
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with Bay 11-7085 or to the combination treatment, except
for the CD40 and CIDEA genes. Specularly, some anti-
apototic genes such as BCL2L2/BCL-W, and BIRC5/sur-
vivin were evidently downregulated following single
treatment with AZT, but even more remarkably following
the combination treatment (Fig. 6b). Also BIRC3/c-IAP2
was downregulated, in comparison with control samples,
but less extensively. Conversely, the expression of other
anti-apoptotic genes, such as TNFS9 and NOL3, was
significantly increased in response to both Bay 11-7085
single treatment and the combination treatment, in
comparison with control samples (Fig. 6b). The bifunc-
tional regulator of apoptosis BFAR and MDM2 genes
were not modulated by the treatments, while TNFRSF14/
HVEM was significantly downregulated in response to all
treatments with respect to control samples (Fig. 6c).
Regarding to C5/MJ cells, all the pro-apoptotic genes
were slightly or not at all modulated following treatment
with AZT alone, but remarkably upregulated, except for
BAX, following the single Bay 11-7085 or the combined
treatments (Fig. 7a). A little differently from what
observed for MT-2 cells, in C5/MJ cells all of the anti-
apoptotic genes, except for TNFSF9 and NOL3, were
downregulated by Bay 11-7085. A specular modulation in
C5/MJ cells was exerted on the same anti-apoptotic genes
by single treatment with AZT, while all the anti-apoptotic
Fig. 6 RQ-PCR analysis of apoptosis-related gene expression in MT-2 cells treated with AZT and an inhibitor of IκBα phosphorylation. MT-2
cells were either treated with vehicle (CTR) or treated with 128 µM AZT alone (AZT), with 1 µM Bay 11-7085 alone (BAY), or with both (AZT+BAY), and
then assayed 24 h after the last treatment for gene-expression by real-time quantitative reverse transcription PCR (RQ-PCR). Normalization of crude
values with the GUSB gene as a housekeeping gene, was performed. Relative gene expression of genes grouped as pro-apoptotic (a), anti-apoptotic
(b), or multi-functional (c), was calculated versus time 0 control samples and is expressed as (log 10). The histograms represent the mean values ± S.D.
from three independent experiments. Asterisks indicate significant (*p < 0.05) and highly significant (**p < 0.001) differences referred to time 24 h CTR
samples.
Matteucci et al. Cell Death Discovery             (2020) 6:9 Page 7 of 13
Official journal of the Cell Death Differentiation Association
genes were, more or less, upregulated by the combination
treatment (Fig. 7a). The bifunctional regulators of apop-
tosis BFAR, MDM2 and TNFRSF14/HVEM were upre-
gulated both by single treatment with AZT and by the
combined treatment, when compared to control, but
downregulated by single treatment with Bay 11-7085.
The expression of viral genes in HTLV-1-transformed
cells in response to the combination treatment with AZT
plus the inhibitor of IκBα phosphorylation, was also
investigated. Results reported in Fig. 8 refers to the
expression of the doubly-spliced Tax/Rex transcripts in
MT-2 cells at 72 h and 6 days after single or combination
treatments, as detected by reverse transcriptase real time
PCR (RT-qPCR). Both AZT alone and AZT plus Bay 11-
7085, but not Bay 11-7085 alone, remarkably and equally
reduced viral gene expression in comparison with control
cells as early as at 72 h after treatment. These effects
persisted also at 6 days after treatment when a partial, but
not significant, reduction in viral transcripts levels was
observed even in Bay 11-7085 treated cells.
Discussion
We have previously demonstrated that knocking out of
IκB rendered U937 cells prone to undergo apoptosis when
Fig. 7 RQ-PCR analysis of apoptosis-related gene expression in C5/MJ cells treated with AZT and an inhibitor of IκBα phosphorylation.
C5/MJ cells were either treated with vehicle (CTR) or treated with 128 µM AZT alone (AZT), with 1 µM Bay 11-7085 alone (BAY), or with both (AZT
+BAY), and then assayed 24 h after the last treatment for gene-expression by real-time quantitative reverse transcription PCR (RQ-PCR). Normalization
of crude values with the GUSB gene as a housekeeping gene, was performed. Relative gene expression of genes grouped as pro-apoptotic (a), anti-
apoptotic (b), or multi-functional (c), was calculated versus time 0 control samples and is expressed as (log 10). The histograms represent the mean
values ± S.D. from three independent experiments. Asterisks indicate significant (*p < 0.05) and highly significant (**p < 0.001) differences referred to
time 24 h CTR samples.
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treated with AZT31, and that a combination treatment
with AZT plus a pharmacological inhibitor of NF-κB
induced, in the same cells, apoptotic RCD associated with
the suppression of anti-apoptotic genes expression and
the upregulation of the mitochondrial apoptotic path-
way32. Thus, the main achievement of this study was the
demonstration that the pharmacological inhibition of NF-
κB activation could prompt also HTLV-1 infected/trans-
formed cells towards RCD when treated with a non-toxic
dose of AZT. Importantly, results showed that this effect
was much less pronounced towards PBMC from healthy
donors, and that a similar selective effect could not be
obtained by using the compounds of the combination
treatment as single agent at whatever concentration.
NF-κB p65/p52 activation, is more heavily regulated in
ATL cells than in healthy cells33. In addition, the rever-
sible NF-κB inhibitor of p65 translocation, DHMEQ,
induced ATL cells to undergo apoptosis in vitro and to
inhibit tumor cell growth in vivo in SCID mice33,34. Thus,
pharmacological inhibition of IκBα phosphorylation has
been proposed as a potential strategy to treat and/or
prevent ATL35. Interestingly, even induction of apoptosis
by IFNα/AZT treatment in ATL cells from patients or in
ATL cell lines has been associated to suppression of NF-
κB activation20. Nevertheless, as shown in our dose–effect
experiments, highly effective concentrations of pharma-
cological inhibitors of NF-κB, are not free from toxicity
towards normal cells. Moreover, results of EMSA or p65
and p52 binding assays, clearly indicate that single treat-
ment with AZT invariably led to increased levels of NF-κB
activation, rather than to a decrease, starting from 24 h
after treatment in HTLV-1 transformed cells. This can
explain resistance to apoptotic RCD in cells exposed to
AZT alone.
To investigate mechanisms underlying the combined
effects of AZT plus Bay11-7085, expression of several
genes associated to cell death/proliferation were assessed
in MT-2 cells, i.e. the HTLV-1-transformed cells that
displayed the higher pro-apoptotic response to the com-
bination treatment. Among the pro-apototic genes, of
particular interest is the noticeable increase, following the
combination treatment, of the expression of the BIM
gene, whose product is a good candidate for triggering an
intrinsic apoptotic cascade in response to AZT plus Bay
11-708536–38. Moreover, a main difference concerned the
expression of anti-apoptotic genes belonging to the IAP
family, such as BIRC5/survivin and BIRC3/c-IAP239–41,
that were dramatically down modulated in MT-2 cells
following the combination treatment. Survivin plays an
important role in oncogenesis42,43 and a survivin inhi-
bitor, YM155, in combination with anti-CD52 mono-
clonal antibodies was shown to increase survival in a
murine model of human ATLL44. Interestingly, a similar,
differential effect on anti-apoptotic genes following the
combination treatment was not observed in C5MJ. Thus,
in general, results of apoptosis-related gene expression
indicate that a short-term combination treatment with
AZT plus Bay 11-7085 induced the upregulation of pro-
apoptotic genes both in MT-2 and in C5/MJ HTLV-1-
transformed cells, while preferentially induced the
downregulation of most of the anti-apoptotic genes in
MT-2 but not in C5/MJ cells. This is in line with a lower
pro-apoptotic response to the combined treatment of C5/
MJ cells in respect to MT-2 cells, in the short time.
Finally, we cannot help highlighting that the combina-
tion treatment with AZT plus Bay 11-7085 significantly
reduced levels of pro-viral gene expression in transformed
cells. We have not a clear explanation, at the moment, for
these data but we can assume that, at the relatively high
concentrations utilized, the nucleoside compound could
exert also an unexpected inhibitory activity on viral
transcripts expression/maturation. The differential
expression of several cellular genes, following therapy
including RT inhibitors, has been amply documented in
HIV-patients45. Interestingly, moreover, the capacity of
AZT to specifically inhibit retroviral gene expression in
cells harboring the HK2 endogenous retrovirus has been
reported, suggesting the possibility that the drug could
actually affect retroviral mRNA transcription46. Our pre-
vious study has shown that in ATL patients who
responded to therapy with AZT plus IFN, HTLV-1 RT
activity was inhibited, while this did not occur in a non-
responder patient (ATL)47. This implies that AZT actually
acts as HTLV-1 RT-inhibitor in vivo. Thus, based on the
results we obtained in the present study, we can hypo-
thesize that presence of AZT in a combination therapy for
Fig. 8 Effects of a combination treatment with AZT and an
inhibitor of IκBα phosphorylation on the expression of the HTLV-
1 doubly-spliced Tax/Rex transcripts in MT-2 cells. MT-2 cells were
treated with vehicle (CTR), with 1 µM Bay 11-7085 (BAY), with 128 µM
AZT (AZT), or both (AZT+BAY) for a total of 3 days in culture (day 3) or,
following a second retreatment with the same protocol, for a total of
6 days in culture (day 6). The histograms represent the mean values ±
S.D. from four independent experiments. Asterisks indicate highly
significant (**p < 0.001) differences referred to corresponding CTR
samples.
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ATL could concomitantly ensure restriction of clonal
expansion of the virus and proneness to RCD of HTLV-1
infected cells.
In conclusion, results of the present study represent a
proof of concept for the addition of an NF-κB inhibitor to
therapeutic regimens including AZT for the treatment of
HTLV-1 related diseases.
Materials and methods
Cell cultures and reagents
The chronically HTLV-1-infected human cell lines MT-
2 (Miyoshi 1981), C91/PL established by co-cultivation of
umbilical cord blood T cells with leukemic T cells from an
ATLL patient (PL)48 and originally obtained from Prof.
Robert Gallo (NINCDS NIH Bethesda MD), and C5/MJ
(ATCC® CRL-8293™, NIH MD), were maintained in
RPMI 1640 medium supplemented with 12% fetal bovine
serum (FBS), 50 U/ml streptomycin, 50 U/ml penicillin
and 2mM glutamine (CM; Gibco- Invitrogen, Paisley,
Scotland, United Kingdom), in a humidified incubator at
37 °C and 5% CO2. The cell lines, here identified as BM24
(CD4+) and BM7 (CD4+/CD8+ double-positive), were
previously infected in vitro with HTLV-1 in our labora-
tory by co-culture of peripheral blood mononuclear cells
(PBMC) from healthy donors with irradiated MT-2.
BM24 and BM7 were utilized in this study at 12 weeks in
culture after infection (a.i), and at 53 weeks in culture
a.i.49, respectively. BM24 and BM7 were still IL-2
dependent, showing their transformation process was
not completed, and were grown in CM in the presence of
20 U of recombinant IL-2 (IL-2; Proleukin, Chiron,
Amsterdam, The Netherlands). PBMC were harvested
from healthy adult donors seronegative for HIV and
hepatitis B and C viruses. Mononuclear cells from hepar-
inized blood were separated using a Ficoll-Hypaque density
gradient (Cedarlane, Hornby, Ontario, Canada). PBMC
were stimulated with and kept in IL-2 at 20 U/ml for 3 and
6 days, respectively. AZT (Sigma-Aldrich, St. Louis, MO,
USA) was diluted in RPMI 1640 and stored at the con-
centration of 32mM; Bay 11-7085 (Sigma) was diluted in
DMSO and stored at 100mM. For the combination
treatment, cells were usually pre-treated for 2 h with Bay
11-7085 before the addition of AZT. Dosages were chosen
on the basis of dose–effect experiments reported in results.
Apoptosis assay
Apoptosis was assessed by flow cytometry analysis of
isolated nuclei following detergent treatment and propi-
dium iodide (PI) staining, using a method that distin-
guishes nuclei from apoptotic, necrotic or viable cells50.
Harvested cells were treated with a solution of PI at
25 mg/ml (Sigma-Aldrich) plus 0.05% sodium citrate
(Sigma-Aldrich) and with detergent at a high concentra-
tion (20% Triton X-100, Sigma-Aldrich) for 30 min and
then placed at 4 °C. Isolated nuclei were then analyzed
using a FACScan flow cytometry (BD Biosciences), until
isolated nuclei were analyzed by fluorescence and by
forward- and side-angle-scatter multiparameter analyses
using a Becton Dickinson FACS analyzer. Cells for ana-
lysis were treated with a mixture consisting of 2% Triton
X-100 (Sigma-Aldrich), 25 μg/ml propidium iodide
(Sigma-Aldrich) and 0.05% sodium citrate (Sigma-
Aldrich). Samples were mixed by gentle inversions for
30min. A minimum of 5000 events per sample were
analyzed. Detectors and amplifier gains for forward and
orthogonal scatter were adequately selected to simulta-
neously detect nuclei from viable, apoptotic and necrotic
cells. Events were gated on forward versus orthogonal
scatter in such a way that degraded DNA from cell debris
or from doublets was excluded and nuclei from viable,
apoptotic and necrotic cells were assayed. Data acquisi-
tion and analysis were performed using CellQuest soft-
ware on a minimum of 5000 events for each sample.
RNA extraction
RNA isolation was performed using a NucleoSpin RNA
kit, and to remove possible DNA contamination, RNA
was treated with RNase-free DNase according to the
manufacturer’s instructions (Machenery-Nagel, Dueren,
Germany). The quantity and the quality of all RNA pre-
parations were assessed by gel electrophoresis and optical
density at 260 nm/optical density at 280 nm ratios.
NF-κB-activity assays
For detecting NF-κB activation by non-radioactive
electro-mobility shift assay (EMSA), nuclear extracts
from cells subjected to different experimental conditions
were prepared as follows. Aliquots of 1 × 107cells were
washed with cold PBS and suspended in 0.4 ml hypotonic
lysis buffer A (10mM HEPES, pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM phe-
nylmethylsulphonyl fluoride, all from Sigma) for 20 min
on ice and homogenized by passing through a 25-gauge
needle. After centrifugation at 12,000 × g for 40 s, nuclear
pellets were resuspended in 20 μl ice-cold buffer B
(20 mM Hepes, pH 7.9, 25% glycerol, 0.42M NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM
PMSF) and supplemented with 1× protease inhibitor
cocktail (Roche Applied Science, Indianapolis, IN, USA).
Following a 20min incubation on ice (with recurring
mixing), samples were centrifuged at 12,000 × g for 5 min
and supernatants containing nuclear extracts were col-
lected, aliquoted and immediately stored at −80 °C.
Before freezing, protein concentration was assessed by
‘DC Protein Assay’ (Bio-Rad Laboratories, Richmond, CA,
USA). The LightShift chemiluminescent EMSA kit
(Pierce, Rockford, IL, USA) was utilized to perform the
EMSA binding reactions. Specifically, 12 μg of nuclear
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extracts were incubated with 10 pmoles of double-
stranded biotinylated probe containing the NF-κB con-
sensus site, and with 1 μg/μl of poly-dI-dC, to prevent
unspecific reaction, in 1× binding buffer for 20min at
room temperature. The complexes were resolved on a 5%
native polyacrylamide/0.5× TBE gel and transferred to a
positive charge nylon membrane (Bio-Rad Laboratories).
After blotting, DNA was cross-linked by UV and signals
from the biotin-labeled probe were detected using
reagents provided in the ‘LightShift chemiluminescent
EMSA module’ (Pierce). Specificity for NF-κB-DNA
binding was validated by addition of 100-fold molar
excess of unlabeled “cold” specific DNA in reaction mix.
Densitometric evaluation of scanned films from three
separate experiments by NIH Image J software (version
1.46r, Bethesda, MD, USA) was performed to quantify
NF-κB-DNA-binding activity. Data were represented as
relative density calculated by the ratio between values
obtained for all samples and values of untreated control
samples at 24 h.
For quantization of NF-κB p65, p50, and p52 binding by
an enzyme-linked immunosorbent assay (ELISA), nuclear
extracts from cells subjected to different treatments were
obtained as described above. Protein concentration of
each sample was determined by BCA protein Assay Kit
(Pierce). The DNA-binding activity of NF-κB p65, p50,
and p52 was measured using a commercial ELISA
according to the manufacturer’s protocol (Trans-AM NF-
κB p65 Transcription Factor Assay Kit; Active Motif
North America, Carlsbad, CA, USA). The absorbance was
determined at 450 nm with wavelength correction 650 nm
using a Labsystem Multiskan Bichromatic spectro-
photometer (Helsinki, Finland).
Transcriptional profile by SuperArray
An amount of 3.5 mg of total RNA was used in a reverse
transcription (RT) reaction with biotin-16-Dutp (Roche
Diagnostics GmbH). RT reaction was performed using
Ampolabelling LPR kit (SABioscience Corporation, Fre-
derick, MD, USA). The labeled cDNA was incubated with
GEArray-Q Series human apoptosis and cell cycle mem-
branes (SuperArray, SABioscience) at 60 °C overnight.
The membrane used in the present study contained 96
genes that were closely related to apoptosis and cell cycle
pathways, in addition to positive control genes (glycer-
aldehydes-3-phosphate dehydrogenase, GAPDH, cyclo-
phillin A, and β-actin). After being washed, the membrane
was incubated with streptavidin-alkaline phosphatase and
was finally exposed to CDP-Star chemiluminescent sub-
strate (SuperArray). Signal detection was performed using
a high Performance chemiluminescence film (Amersham
Biosciences). Analysis of results was performed by
GEArray Expression Analysis Suite software (http://
geasuite.superarray.com). According to this analysis,
transcriptional levels of genes showing fold change values
of >1.50 or <0.66 were considered significantly modified.
Real-time quantitative reverse transcription PCR
The transcriptional activity of the genes of interest was
evaluated by real-time quantitative reverse transcription
PCR (RQ-PCR), using a CFX-96 real-time instrument
(Bio-Rad) and cDNA specific primers purchased from
Primm (Milan, Italy). The list of genes assayed and the
corresponding sequences of the primers utilized are
reported in Supplementary Information (SI) 1. To evalu-
ate HTLV-1 mRNA expression, RPXPR1 and RPX4 pri-
mers specific for the Tax/Rex splicing region were used51.
For reverse-transcription, 0.25 μg of total RNA extracted
from each experimental sample were processed for cDNA
generation using a high capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems), according to the
manufacturer’s instructions. RQ-PCR was performed as
previously described in detail52 and mRNA levels were
calculated referring to glucuronidase beta (GUSB) as a
housekeeping gene. Then, to compare the expression of
each gene in the different treatment conditions, the
relative expression was calculated using the equation
2−ΔΔCt where ΔΔCt=ΔCt (treated)−ΔCt (control), and
ΔCt (treated)= [Ct (target gene)−Ct (GUSB)]treated as
well as ΔCt (control)= [Ct (target gene)−Ct (GUSB)]
control.
Statistical analysis
Each experiment was performed in triplicate with dif-
ferent replicates for sample, except one case when only
two independent experiments were performed, as stated
in the related legend of the Fig. 8. All data are presented as
mean ± S.D. Data analysis was performed using the SPSS
statistical software system (version 17.0 for Windows,
Chicago, IL). For comparison of the means, the Bonfer-
roni’s post-hoc multiple comparison ANOVA test was
utilized. Results of the statistical tests are reported in the
figures as: (*) for p < 0.05 and (**) for p < 0.001.
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